Saturday, November 23, 2024

ReNAgade Therapeutics appoints Laurie Stelzer as chief financial officer

ReNAgade Therapeutics is a company aiming to unlock the unlimited potential of RNA medicines. the company announced the appointment of Laurie Stelzer as chief financial officer. Ms. Stelzer previously served as Chief Financial Officer of Mirati Therapeutics and has more than 25 years of experience. She will further strengthen ReNAgade’s leadership team.

Amit D. Munshi, CEO of ReNAgade, said: “Laurie is an exceptional leader with extensive experience in the pharmaceutical and biotechnology industries, working across corporate finance and strategy, business development, and helping companies build solutions that deliver benefits to their stakeholders. The key capabilities needed for researchers to create long-term value. I have worked with Laurie for more than 20 years, and I am very excited to welcome her to ReNAgade’s leadership team as our first CFO to continue to advance our scientific progress and company growth.”

Also Read : Neogen® Wins Best Innovative Luminol-Based Substrate Award

Ms. Stelzer said, “ReNAgade is focused on bringing RNA medicines to previously unreachable tissues and cells in the human body as it advances its industry-leading platform. I am excited about the opportunity to help shape and support the development of ReNAgade and RNA as a whole.” Advances in Medicine.”

Ms. Stelzer has more than 25 years of experience supporting financial functions at biopharmaceutical companies, most recently as Chief Financial Officer of Mirati Therapeutics. Previously, she served as chief financial officer of Arena Pharmaceuticals, where she helped lead the company’s $6.7 billion acquisition by Pfizer. She was also chief financial officer of Halozyme Therapeutics, where she led the company’s finance, IT, business development and program management functions. She also held senior management positions at Shire, including senior vice president of finance, chief financial officer of the regenerative medicine division and head of investor relations. She began her biotechnology career at Amgen, where she spent 15 years in positions of increasing responsibility in finance, global commercial operations, treasury and international/emerging markets. Laurie earned a bachelor’s degree in accounting from Arizona State University and an MBA from the UCLA Anderson School of Management.

SOURCE : BusinessWire

Subscribe Now

    Hot Topics